European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment
WERNER R.N.; NIKKELS, Arjen; MARINOVIC B.et al.
2017 • In Journal of the European Academy of Dermatology and Venereology, p. 20-37
[en] Herpes zoster (HZ, shingles) is a frequent medical condition which may severely impact the quality of life of affected patients. Different therapeutic approaches to treat acute HZ are available. The aim of this European project was the elaboration of a consensus-based guideline on the management of patients who present with HZ, considering different patient populations and different localizations. This interdisciplinary guideline aims at an improvement of the outcomes of the acute HZ management concerning disease duration, acute pain and quality of life of the affected patients and at a reduction in the incidence of postherpetic neuralgia (PHN) and other complications. The guideline development followed a structured and pre-defined process, considering the quality criteria for guidelines development as suggested by the AGREE II instrument. The steering group was responsible for the planning and the organization of the guideline development process (Division of Evidence-Based Medicine, dEBM). The expert panel was nominated by virtue of clinical expertise and/or scientific experience and included experts from the fields of dermatology, virology/infectiology, ophthalmology, otolaryngology, neurology and anaesthesiology. Recommendations for clinical practice were formally consented during the consensus conference, explicitly considering different relevant aspects. The guideline was approved by the commissioning societies after an extensive internal and external review process. In this second part of the guideline, therapeutic interventions have been evaluated. The expert panel formally consented recommendations for the treatment of patients with HZ (antiviral medication, pain management, local therapy), considering various clinical situations. Users of the
guideline must carefully check whether the recommendations are appropriate for the context of intended application. In the setting of an international guideline, it is generally important to consider different national approaches and legal circumstances with regard to the regulatory approval, availability and reimbursement of diagnostic and therapeutic interventions.
Disciplines :
Dermatology
Author, co-author :
WERNER R.N.
NIKKELS, Arjen ; Centre Hospitalier Universitaire de Liège - CHU > Service de dermatologie
European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment
Publication date :
January 2017
Journal title :
Journal of the European Academy of Dermatology and Venereology
AGREE Next Steps Consortium. The AGREE II Instrument. 2009. http://www.agreetrust.org (last accessed: 03 June 2016).
Andrews J, Guyatt G, Oxman AD et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719–725.
McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed) 1986; 293: 1529–1532.
Huff JC, Bean B, Balfour HH Jr et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988; 85: 84–89.
Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988; 85: 79–83.
Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102: 93–95.
Tyring S, Barbarash RA, Nahlik JE et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123: 89–96.
Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341–347.
Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39: 1546–1553.
Lin WR, Lin HH, Lee SS et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect 2001; 34: 138–142.
Shen MC, Lin HH, Lee SS, Chen YS, Chiang PC, Liu YC. Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster. J Microbiol Immunol Infect 2004; 37: 75–81.
Shafran SD, Tyring SK, Ashton R et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004; 29: 248–253.
Wassilew SW, Wutzler P. Brivddin Herpes Zoster Study G. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 2003; 59: 49–56.
Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9: 863–869.
Degreef H. Famciclovir Herpes Zoster Clinical Study G. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994; 4: 241–246.
Ono F, Yasumoto S, Furumura M et al. Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster. J Dermatol 2012; 39: 902–908.
Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2014; 2: CD006866.
Wassilew SW, Wutzler P. Brivddin Herpes Zoster Study G. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res 2003; 59: 57–60.
Wassilew S. Collaborative Brivudin PHNSG. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 2005; 19: 47–55.
Neoh C, Harding SP, Saunders D et al. Comparison of topical and oral acyclovir in early herpes zoster ophthalmicus. Eye (Lond) 1994; 8(Pt 6): 688–691.
Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000; 107: 1507–1511.
Tyring S, Engst R, Corriveau C et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol 2001; 85: 576–581.
Balfour HH Jr, Bean B, Laskin OL et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308: 1448–1453.
Wutzler P, De Clercq E, Wutke K, Farber I. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 1995; 46: 252–257.
Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med 1986; 314: 208–212.
Dworkin RH, Johnson RW, Breuer J et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44(Suppl 1): S1–S26.
Gross G, Schofer H, Wassilew S et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003; 26: 277–289; discussion 91-3.
Wood MJ, Johnson RW, Mckendrick MW, Taylor J, Mandal BK, Crooks J. A Randomized Trial of Acyclovir for 7 Days or 21 Days with and without Prednisolone for Treatment of Acute Herpes-Zoster. N Engl J Med 1994; 330: 896–900.
Pleyer U, Chee SP. Current aspects on the management of viral uveitis in immunocompetent individuals. Clin Ophthalmol 2015; 9: 1017–1028.
Wong RW, Jumper JM, McDonald HR et al. Emerging concepts in the management of acute retinal necrosis. Br J Ophthalmol 2013; 97: 545–552.
Tibbetts MD, Shah CP, Young LH, Duker JS, Maguire JI, Morley MG. Treatment of acute retinal necrosis. Ophthalmology 2010; 117: 818–824.
Turner JE, Geunes PM, Schuman NJ. Cranial polyneuropathy - Ramsay Hunt's syndrome - Case report and discussion. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83: 354–357.
Hall SJ, Kerr AG. Acyclovir in Herpes-Zoster Oticus. Lancet 1985; 1: 1103.
Stafford FW, Welch AR. The Use of Acyclovir in Ramsay Hunt Syndrome. J Laryngol Otol 1986; 100: 337–340.
Dickins JR, Smith JT, Graham SS. Herpes zoster oticus: treatment with intravenous acyclovir. Laryngoscope 1988; 98: 776–779.
de Ru JA, van Benthem PPG. Combination Therapy Is Preferable for Patients With Ramsay Hunt Syndrome. Otology & Neurotology 2011; 32: 852–855.
Pasternak B, Hviid A. Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects. JAMA J Am Med Assoc 2010; 304: 859–866.
Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical company commitment. Am J Obstet Gynecol 2000; 182: 159–163.
Guess HA, Broughton DD, Melton LJ 3rd, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics 1985; 76: 512–517.
Petursson G, Helgason S, Gudmundsson S, Sigurdsson JA. Herpes zoster in children and adolescents. Pediatr Infect Dis J 1998; 17: 905–908.
Safrin S, Berger TG, Gilson I et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991; 115: 19–21.
Saint-Leger E, Caumes E, Breton G et al. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 33: 2061–2067.
Wauters O, Lebas E, Nikkels AF. Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections. J Am Acad Dermatol 2012; 66: e217–e227.
Breton G, Fillet AM, Katlama C, Bricaire F, Caumes E. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis 1998; 27: 1525–1527.
Schliefer K, Gumbel HO, Rockstroh JK, Spengler U. Management of progressive outer retinal necrosis with cidofovir in a human immunodeficiency virus-infected patient. Clin Infect Dis 1999; 29: 684–685.
Wiegering V, Schick J, Beer M et al. Varicella-zoster virus infections in immunocompromised patients - a single centre 6-years analysis. BMC Pediatr 2011; 11: 31.
Zambarakji HJ, Obi AA, Mitchell SM. Successful treatment of varicella zoster virus retinitis with aggressive intravitreal and systemic antiviral therapy. Ocul Immunol Inflamm 2002; 10: 41–46.
Baron R, Tolle TR, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain 2009; 146: 34–40.
Cohen JI. Herpes Zoster. N Engl J Med 2013; 369: 255–263.
Whitley RJ. A 70-Year-Old Woman With Shingles Review of Herpes Zoster. JAMA J Am Med Assoc 2009; 302: 73–80.
Whitley RJ, Volpi A, McKendrick M, van Wijck A, Oaklander AL. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol 2010; 48: S20–S28.
Edelsberg JS, Lord C, Oster G. Systematic Review and Meta-Analysis of Efficacy, Safety, and Tolerability Data from Randomized Controlled Trials of Drugs Used to Treat Postherpetic Neuralgia. Ann Pharmacother 2011; 45: 1483–1490.
Forbes HJ, Thomas SL, Smeeth L et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 2016; 157: 30–54.
Erlenwein J, Thoms KM, Brandebusemeyer F et al. Pre-Existing Chronic Pain Influences the Severity of Acute Herpes Zoster Pain-A Prospective Observational Cohort Study. Pain Med 2016 [Epub ahead of print].
Haanpaa M, Attal N, Backonja M et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011; 152: 14–27.
Rothaug J, Zaslansky R, Schwenkglenks M et al. Patients’ perception of postoperative pain management: validation of the International Pain Outcomes (IPO) questionnaire. J Pain 2013; 14: 1361–1370.
Bartley J. Post herpetic neuralgia, schwann cell activation and vitamin D. Med Hypotheses 2009; 73: 927–929.
Zhang J, Echeverry S, Lim TKY, Lee SH, Shi XQ, Huang H. Can Modulating Inflammatory Response be a Good Strategy to Treat Neuropathic Pain? Curr Pharm Des 2015; 21: 831–839.
World Health Organization. Cancer pain relief: with a guide to opioid availability. 2nd ed., Geneva: World Health Organization, 1996.
Dworkin RH, Barbano RL, Tyring SK et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009; 142: 209–217.
Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005; 65: 444–447.
Meister W, Neiss A, Gross G et al. A prognostic score for postherpetic neuralgia in ambulatory patients. Infection 1998; 26: 359–363.
Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev 2014; 7: CD010958.
McGill J, Chapman C. A comparison of topical acyclovir with steroids in the treatment of herpes zoster keratouveitis. Br J Ophthalmol 1983; 67: 746–750.
Marsh RJ, Cooper M. Double-masked trial of topical acyclovir and steroids in the treatment of herpes zoster ocular inflammation. Br J Ophthalmol 1991; 75: 542–546.
Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008; 115: S3–S12.
